BPC-157 Dosage: What Published Research Actually Used (and Why No One Can Recommend a Human Dose)
- Written by
- Daniel Reyes, PhD
- Medically reviewed by
- Dr. Sarah Lindqvist, MD
- Published
- June 20, 2025
- Updated
- June 20, 2025
- Last medical review
- June 20, 2025
- Reviewer scope
- Metabolic health
There is no established human dose of BPC-157, because no adequately powered human trial has ever defined one. The numbers circulating online — commonly 200–500 mcg daily — are extrapolations from rodent studies that used roughly 10 mcg/kg body weight. BPC-157 is not FDA-approved and appears on the FDA list of compounding substances with significant safety risks. Dosing, if any, is a licensed clinician’s decision.
Regulatory status first
BPC-157 is not approved by the FDA for any use, and the agency has named it among bulk substances that may present significant safety risks when compounded. That means no validated human dose, no manufacturing oversight of gray-market vials, and no adverse-event surveillance.
What the rodent literature used
The most-cited tendon work administered approximately 10 mcg/kg in rats, by injection or orally in drinking water, across days to weeks. Scaling rodent doses to humans is not simple multiplication — interspecies allometric scaling, route differences, and the absence of human pharmacokinetics make any converted number a guess.
Why "dosage protocols" online disagree with each other
Because none of them are anchored to human data. Per-body-weight charts, per-day totals, and cycle rules all trace back to the same rodent studies filtered through forum tradition. When sources with no data disagree, the disagreement is the finding.
The chart phenomenon deserves its own autopsy — our BPC-157 dosage chart breakdown reverse-engineers the numbers. Route questions live in how to take BPC-157, duration folklore in the cycle-length review, and the underlying injury data in the tendon-repair evidence file. The compound’s full profile is in our BPC-157 monograph.
What we will and will not do
This page reports what published studies and regulatory documents describe. It never recommends a dose — dosing is a clinical decision for a licensed prescriber who knows your history. Our reconstitution calculator performs the measurement arithmetic for a dose your prescriber supplies — that is the whole scope of responsible tooling here.
Frequently asked questions
What is the recommended dosage of BPC-157?
Where do the 250–500 mcg BPC-157 numbers come from?
Is BPC-157 FDA-approved?
What doses did BPC-157 animal studies use?
Questions to ask a licensed clinician
- Is there any human evidence relevant to my injury?
- If prescribed, how would purity and sterility be verified?
- What proven standard-of-care should come first?
References
- Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. SourcePreclinical
- Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. SourceNarrative review
- US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice
Related tools
Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.